Why have nanotechnologies been underutilized in the global uprising against the coronavirus pandemic?

Vuk Uskoković, Vuk Uskoković

Abstract

Prior research on nanotechnologies in diagnostics, prevention and treatment of coronavirus infections is reviewed. Gold nanoparticles and semiconductor quantum dots in colorimetric and immunochromatographic assays, silica nanoparticles in the polymerase chain reaction and spike protein nanospheres as antigen carriers and adjuvants in vaccine formulations present notable examples in diagnostics and prevention, while uses of nanoparticles in coronavirus infection treatments have been merely sporadic. The current absence of antiviral therapeutics that specifically target human coronaviruses, including SARS-CoV-2, might be largely due to the underuse of nanotechnologies. Elucidating the interface between nanoparticles and coronaviruses is timely, but presents the only route to the rational design of precisely targeted therapeutics for coronavirus infections. Such a fundamental approach is also a viable prophylaxis against future pandemics of this type.

Keywords: COVID-19; infectious disease; interface; nanoparticle; nanotechnology; vaccine.

Figures

Figure 1.. Bibliographic analysis.
Figure 1.. Bibliographic analysis.
Total annual number of publications listed in the United States National Library of Medicine and containing the following keywords: ‘nanoparticles’ and either ‘cancer’ or ‘viral’; (A) ‘hepatitis’ or ‘coronavirus’; (B) ‘H1N1’ or ‘MERS-CoV’ (C). Search was performed at https://www.ncbi.nlm.nih.gov/pubmed/ on 14 March 2020. Total number of patents filed in the United States Patent Office and containing the word ‘nanoparticles’, the word ‘coronavirus’ or both of these words in the claims for the period 1976–2020 (D). Search was performed at https://patft.uspto.gov/netahtml/PTO/search-adv.htm using the ‘aclm/(keyword and keyword)’ operator on 15 March 2020. MERS-CoV: Middle East respiratory syndrome-related coronavirus.
Figure 2.. Nanotechnologies in coronavirus research.
Figure 2.. Nanotechnologies in coronavirus research.
(A) Transmission electron micrograph of SARS-CoV viral particles entering a Vero E6 host cell by binding to the cell surface receptor (upper left arrow), then having their envelopes fuse with the cell membrane (central arrow) and nucleocapsids enter the cell (arrowhead). Bar is 100 nm. Reproduced with permission from [53], licensed with CC BY 3.0. (B) Poly(D,L-lactide-co-glycolide) nanoparticles loaded with inactive PEDV antigens (PLGA-KAg) increasing IgG and neutralizing antibody titers in sows relative to the titers in sows treated with saline and sows inoculated with the antigen alone (KAg and 201-KAg). Bar is 100 nm. Reproduced with permission from [68] © Elsevier (2017). (C) Schematic representation of a protein cage nanoparticle showing individual protein subunits and the survival of mice infected with SARS-CoV after the treatment with saline (empty triangles) or with the protein cage nanoparticles (black squares). Reproduced with permission from [83], licensed with CC BY 3.0. (D) Toluidine blue staining of the fore paws of the vehicle control mice showing moderate inflammation and cartilage damage with moderate pannus and bone resorption in all the joints and of mice treated with the SARS-CoV-derived peptide MWKTPTLKYFG (MG11) delivered with spherical high-density lipopeptide nanoparticles, showing no inflammation and minimal cartilage damage. Arrows identify affected joints. Tipped W denotes the wrist. Reproduced with permission from [112], licensed with CC BY 4.0. PBS: Phosphate-buffered saline; PEDV: Porcine epidemic diarrhea virus; PLGA: Poly(D,L-lactide-co-glycolide); sHDL: Spherical high-density lipopeptide nanoparticles.

References

    1. Ryan FP. Viral symbiosis and the holobiontic nature of the human genome. APMIS 124(1–2), 11–19 (2016).
    1. Blinov VM, Zverev VV, Krasnov GS, Filatov FP, Shargunov AV. Viral component of the human genome. Mol. Biol. (Mosk.) 51(2), 240–250 (2017).
    1. Johnson BA, Graham RL, Menachery VD. Viral metagenomics, protein structure, and reverse genetics: key strategies for investigating coronaviruses. Virology 517, 30–37 (2018).
    1. Li F. Structure, function, and evolution of coronavirus spike proteins. Ann. Rev. Virol. 3, 237–261 (2016).
    1. Du L, Yang Y, Zhou Y, Lu L, Li F, Jiang S. MERS-CoV spike protein: a key target for antivirals. Expert Opin. Ther. Targets 21(2), 131–143 (2017).
    1. Elena SF, Sanjuan R. Adaptive value of high mutation rates of RNA viruses: separating causes from consequences. J. Virol. 79(18), 11555–11558 (2005).
    1. Domingo E. Quasispecies theory in virology. J. Virol. 76, 463–465 (2002).
    1. Uskoković V. Nanotechnologies: what we do not know. Tech. Soc. 29(1), 43–61 (2007).

    2. • First study to provide a methodologically critical view of nanotechnology amidst an overwhelming confidence in its analytical frameworks.

    1. Uskoković V. Challenges for the modern science in its descend towards nano scale. Curr. Nanosci. 5(3), 372–389 (2009).
    1. Uskoković V. Entering the era of nanoscience: time to be so small. J. Biomed. Nanotech. 9, 1441–1470 (2013).
    1. Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J. Drug Target. 24(3), 179–191 (2016).
    1. Harwansh RK, Deshmukh R, Barkat MA, Rahman MA. Bioinspired polymeric-based core-shell smart nano-systems. Pharm. Nanotechnol. 7(3), 181–205 (2019).
    1. Goldberg MS. Improving cancer immunotherapy through nanotechnology. Nat. Rev. Cancer 19(10), 587–602 (2019).
    1. Uskoković V, Lee K, Lee PP, Fischer KE, Desai TA. Shape effect in the design of nanowire-coated microparticles as epithelial drug delivery devices. ACS Nano 6(9), 7832–7841 (2012).
    1. Uskoković V. Nanostructured platforms for the sustained and local delivery of antibiotics in the treatment of osteomyelitis. Crit. Rev. Ther. Drug Carrier Syst. 32(1), 1–59 (2015).
    1. Neuman BW, Adair BD, Yoshioka C. et al. Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy. J. Virol. 80(16), 7918–7928 (2006).
    1. Barcena M, Oostergetel GT, Bartelink W. et al. Cryo-electron tomography of mouse hepatitis virus: insights into the structure of the coronavirion. Proc. Natl Acad. Sci. USA 106(2), 582–587 (2009).
    1. Li W, Hulswit RJG, Widjaja I. et al. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. Proc. Natl Acad. Sci. USA 114(40), E8508–E8517 (2017).
    1. Uskoković V, Desai TA. Does translational symmetry matter on the micro scale? Fibroblastic and osteoblastic interactions with the topographically distinct poly(ϵ-caprolactone)/hydroxyapatite thin films. ACS Appl. Mater. Interfaces 6(15), 13209–13220 (2014).
    1. Barthold SW, Bowen RA, Hedrick RP. et al. Epidemiology and control of viral diseases. : Fenner’s Veterinary Virology (4th Edition). MacLachlan NJ, Dubovi EJ (). Elsevier, Amsterdam, The Netherlands, 125–148 ( 2011).
    1. Davis DJ. Measurements of the prevalence of viral infections. J. Infect. Dis. 133(Suppl. 2), A3–A5 (1976).
    1. NIH National Cancer Institute. Cancer statistics (2018).
    1. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) – update (2016).
    1. Kim H, Park M, Hwang J. et al. Development of label-free colorimetric assay for MERS-CoV using gold nanoparticles. ACS Sens. 4(5), 1306–1312 (2019).
    1. Park TJ, Lee SY, Lee SJ. et al. Protein nanopatterns and biosensors using gold binding polypeptide as a fusion partner. Anal. Chem. 78(20), 7197–7205 (2006).
    1. Bian H, Xu F, Jia Y. et al. A new immunochromatographic assay for on-site detection of porcine epidemic diarrhea virus based on monoclonal antibodies prepared by using cell surface fluorescence immunosorbent assay. BMC Vet. Res. 15(1), 32 (2019).
    1. Layqah LA, Eissa S. An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes. Mikrochim. Acta 186(4), 224 (2019).
    1. Huang JC, Chang YF, Chen KH. et al. Detection of severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in human serum using a localized surface plasmon coupled fluorescence fiber-optic biosensor. Biosens. Bioelectron. 25, 320–325 (2009).
    1. Teengam P, Siangproh W, Tuantranont A, Vilaivan T, Chailapakul O, Henry CS. Multiplex paper-based colorimetric DNA sensor using pyrrolidinyl peptide nucleic acid-induced AgNPs aggregation for detecting MERS-CoV, MTB, and HPV oligonucleotides. Anal. Chem. 89(10), 5428–5435 (2017).
    1. Gong P, He X, Wang K. et al. Combination of functionalized nanoparticles and polymerase chain reaction-based method for SARS-CoV gene detection. J. Nanosci. Nanotechnol. 8(1), 293–300 (2008).

    2. • Earliest study on the use of polymerase chain reaction (PCR) in coronavirus diagnostics.

    1. Yuan W, Li Y, Li P, Song Q, Li L, Sun J. Development of a nanoparticle-assisted PCR assay for detection of porcine epidemic diarrhea virus. J. Virol. Methods 220, 18–20 (2015).
    1. Zhu Y, Wang GH, Cui YD, Cui SJ. Establishment of a nanoparticle-assisted RT-PCR assay to distinguish field strains and attenuated strains of porcine epidemic diarrhea virus. Arch. Virol. 161(9), 2543–2547 (2016).
    1. Huang Y, Xing N, Wang Z. et al. Ultrasensitive detection of RNA and DNA viruses simultaneously using duplex UNDP-PCR Assay. PLoS ONE 10(11), e0141545 (2015).
    1. Zhu Y, Liang L, Luo Y. et al. A sensitive duplex nanoparticle-assisted PCR assay for identifying porcine epidemic diarrhea virus and porcine transmissible gastroenteritis virus from clinical specimens. Virus Genes 53(1), 71–76 (2017).
    1. Xing N, Guan X, An B. et al. Ultrasensitive detection of porcine epidemic diarrhea virus from fecal samples using functionalized nanoparticles. PLoS ONE 11(12), e0167325 (2016).
    1. Sang FM, Li X, Liu J. Development of nano-polymerase chain reaction and its application. Chin. J. Anal. Chem. 45, 1745–1753 (2017).
    1. Hamdy ME, Carlo MD, Hussein HA. et al. Development of gold nanoparticles biosensor for ultrasensitive diagnosis of foot and mouth disease virus. J. Nanobiotechnol. 16, 48 (2018).
    1. Wang J, Cheng Y, Zhang M. et al. Development of a nanoparticle-assisted PCR (nanoPCR) assay for detection of mink enteritis virus (MEV) and genetic characterization of the NS1 gene in four Chinese MEV strains. BMC Vet. Res. 11, 1 (2015).
    1. Sang F, Yang Y, Wang J, Huang X, Ren J, Zhang Z. Quantum dots trigger hot-start effects for pfu-based polymerase chain reaction. J. Exp. Nano. 10, 476–482 (2015).
    1. Li M, Lin YC, Wu CC, Liu HS. Enhancing the efficiency of a PCR using gold nanoparticles. Nucleic Acids Res. 33, e184 (2005).
    1. Liu Z, Li J, Liu Z. et al. Development of a nanoparticle-assisted PCR assay for detection of bovine respiratory syncytial virus. BMC Vet. Res. 15(1), 110 (2019).
    1. Wanzhe Y, Jianuan L, Peng L, Jiguo S, Ligong C, Juxiang L. Development of a nano-particle-assisted PCR assay for detection of duck tembusu virus. Lett. Appl. Microbiol. 62(1), 63–67 (2016).
    1. Park TJ, Lee SK, Yoo SM, Yang SM, Lee SY. Development of reflective biosensor using fabrication of functionalized photonic nanocrystals. J. Nanosci. Nanotechnol. 11(1), 632–637 (2011).
    1. Roh C. A facile inhibitor screening of SARS coronavirus N protein using nanoparticle-based RNA oligonucleotide. Int. J. Nanomedicine 7, 2173–2179 (2012).
    1. Yang S, Li L, Yin S. et al. Single-domain antibodies as promising experimental tools in imaging and isolation of porcine epidemic diarrhea virus. Appl. Microbiol. Biotechnol. 102(20), 8931–8942 (2018).
    1. Ahmed SR, Kang SW, Oh S, Lee J, Neethirajan S. Chiral zirconium quantum dots: a new class of nanocrystals for optical detection of coronavirus. Heliyon 4(8), e00766 (2018).
    1. Ma J, Wu L, Li Z. et al. Versatile electrochemiluminescence assays for PEDV antibody based on rolling circle amplification and Ru-DNA nanotags. Anal. Chem. 90(12), 7415–7421 (2018).
    1. Liu IL, Lin YC, Lin YC, Jian CZ, Cheng IC, Chen HW. A novel immunochromatographic strip for antigen detection of avian infectious bronchitis virus. Int. J. Mol. Sci. 20(9), 2216 (2019).
    1. Broughton JP, Deng X, Yu G. et al. Rapid detection of 2019 novel coronavirus SARS-CoV-2 using a CRISPR-based DETECTR lateral flow assay. MedRxiv ( (2020) (Preprint).
    1. Udugama B, Kadhiresan P, Kozlowski HN. et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano 14(4), 3822–3835 (2020).

    2. • A succinct up-to-date review on methods for the detection of SARS-CoV-2.

    1. Seth A, Ritchie FK, Wibowo N, Lua LHL, Middelberg APJ. Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner. PLoS ONE 10(3), e0117203 (2015).
    1. Yue H, Wei W, Fan B. et al. The orchestration of cellular and humoral responses is facilitated by divergent intracellular antigen trafficking in nanoparticle-based therapeutic vaccine. Pharmacol. Res. 65(2), 189–197 (2012).
    1. Liu Z, Liu S, Cui J, Tan Y, He J, Zhang J. Transmission electron microscopy studies of cellular responses to entry of virions: one kind of natural nanobiomaterial. Int. J. Cell Biol. 2012, 596589 (2012).
    1. Coleman CM, Liu YV, Mu H. et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32(26), 3169–3174 (2014).
    1. Coleman CM, Venkataraman T, Liu YV. et al. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine 35(12), 1586–1589 (2017).
    1. Jung SY, Kang KW, Lee EY. et al. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. Vaccine 36(24), 3468–3476 (2018).
    1. Kam YW, Kien F, Roberts A. et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FccRII-dependent entry into B cells in vitro. Vaccine 25, 729–740 (2007).
    1. Czub M, Weingartl H, Czub S, He R, Cao J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 23, 2273–2279 (2005).
    1. Bolles M, Deming D, Long K. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201–12215 (2011).
    1. Sekimukai H, Iwata-Yoshikawa N, Fukushi S. et al. Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs. Microbiol. Immunol. 64(1), 33–51 (2020).
    1. Pimentel TA, Yan Z, Jeffers SA, Holmes KV, Hodges RS, Burkhard P. Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem. Biol. Drug Des. 73(1), 53–61 (2009).

    2. • Earliest study on the use of nanoparticles as adjuvants in a vaccine that protects against a coronavirus.

    1. Li J, Helal ZH, Karch CP. et al. A self-adjuvanted nanoparticle based vaccine against infectious bronchitis virus. PLoS ONE 13(9), e0203771 (2018).
    1. Kato T, Takami Y, Kumar Deo V, Park EY. Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells. J. Biotechnol. 306, 177–184 (2019).
    1. Raman S, Machaidze G, Lustig A, Aebi U, Burkhard P. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. Nanomedicine 2(2), 95–102 (2006).
    1. Lopez-Sagaseta J, Malito E, Rappuoli R, Bottomley MJ. Self-assembling protein nanoparticles in the design of vaccines. Comput. Struct. Biotechnol. J. 14, 58–68 (2016).
    1. Kim YS, Son A, Kim J. et al. Chaperna-mediated assembly of ferritin-based Middle East respiratory syndrome-coronavirus nanoparticles. Front. Immunol. 9, 1093 (2018).
    1. Shim BS, Park SM, Quan JS. et al. Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses. BMC Immunol. 11, 65 (2010).
    1. Li B, Du L, Yu Z. et al. Poly(D,L-lactide-co-glycolide) nanoparticle-entrapped vaccine induces a protective immune response against porcine epidemic diarrhea virus infection in piglets. Vaccine 35(50), 7010–7017 (2017).
    1. Lopes PD, Okino CH, Fernando FS. et al. Inactivated infectious bronchitis virus vaccine encapsulated in chitosan nanoparticles induces mucosal immune responses and effective protection against challenge. Vaccine 36(19), 2630–2636 (2018).
    1. Raghuwanshi D, Mishra V, Das D, Kaur K, Suresh MR. Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS-CoV nucleocapsid protein. Mol. Pharm. 9(4), 946–956 (2012).
    1. Zhao K, Li S, Li W. et al. Quaternized chitosan nanoparticles loaded with the combined attenuated live vaccine against Newcastle disease and infectious bronchitis elicit immune response in chicken after intranasal administration. Drug Deliv. 24(1), 1574–1586 (2017).
    1. Uskoković V, Desai TA. In vitro analysis of nanoparticulate hydroxyapatite/chitosan composites as potential drug delivery platforms for the sustained release of antibiotics in the treatment of osteomyelitis. J. Pharm. Sci. 103(2), 567–579 (2014).
    1. Ignjatović NL, Penov-Gaši KM, Wu VM. et al. Selective anticancer activity of lung-targeting hydroxyapatite/chitosan-poly(D,L)-lactide-co-glycolide particles loaded with an androstane-based cancer inhibitor. Coll. Surf. B 148, 629–639 (2016).
    1. Ciejka J, Wolski K, Nowakowska M, Pyrc K, Szczubialka K. Biopolymeric nano/microspheres for selective and reversible adsorption of coronaviruses. Mater. Sci. Eng. C Mater. Biol. Appl. 76, 735–742 (2017).
    1. Staroverov SA, Vidyasheva IV, Gabalov KP, Vasilenko OA, Laskavyi VN, Dykman LA. Immunostimulatory effect of gold nanoparticles conjugated with transmissible gastroenteritis virus. Bull. Exp. Biol. Med. 151(4), 436–439 (2011).

    2. • Earliest study on the use of nanoparticles in the treatment of coronavirus infection.

    1. Staroverov SA, Volkov AA, Mezhenny PV. et al. Prospects for the use of spherical gold nanoparticles in immunization. Appl. Microbiol. Biotechnol. 103(1), 437–447 (2019).
    1. Chen HW, Huang CY, Lin SY. et al. Synthetic virus-like particles prepared via protein corona formation enable effective vaccination in an avian model of coronavirus infection. Biomaterials 106, 111–118 (2016).
    1. Zhang XF, Liu ZG, Shen W, Gurunathan S. Silver nanoparticles: synthesis, characterization, properties, applications, and therapeutic approaches. Int. J. Mol. Sci. 17(9), E1534 (2016).
    1. Lv X, Wang P, Bai R. et al. Inhibitory effect of silver nanomaterials on transmissible virus-induced host cell infections. Biomaterials 35(13), 4195–4203 (2014).
    1. Ye S, Shao K, Li Z. et al. Antiviral activity of graphene oxide: how sharp edged structure and charge matter. ACS Appl. Mater. Interfaces 7(38), 21571–21579 (2015).
    1. Chen YN, Hsueh YH, Hsieh CT, Tzou DY, Chang PL. Antiviral activity of graphene-silver nanocomposites against non-enveloped and enveloped viruses. Int. J. Environ. Res. Public Health 13(4), 430 (2016).
    1. Hu CJ, Chang WS, Fang ZS. et al. Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus. Sci. Rep. 7(1), 13043 (2017).
    1. Wiley JA, Richert LE, Swain SD. et al. Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. PLoS ONE 4(9), e7142 (2009).

    2. • Earliest study reporting on the use of nanoparticles to mitigate coronavirus infection.

    1. Quinton LJ, Mizgerd JP, Hilliard KL, Jones MR, Kwon CY, Allen E. Leukemia inhibitory factor signaling is required for lung protection during pneumonia. J. Immunol. 188(12), 6300–6308 (2012).
    1. Metcalfe SM, Strom TB, Williams A, Fahmy TM. Multiple sclerosis and the LIF/IL-6 axis: use of nanotechnology to harness the tolerogenic and reparative properties of LIF. Nanobiomedicine 2, 5 (2015).
    1. Rittchen S, Boyd A, Burns A. et al. Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF). Biomaterials 56, 78–85 (2015).
    1. Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2), 271–280 (2020).

    2. • Study performed in the midst of the SARS-CoV-2 pandemic, elucidating the cell entrance mechanism employed by the virus.

    1. Udristioiu A. Molecular mechanisms and methods used to detect COVID-19 infection. CORDIS European Commission News No. 415876 (2020).
    1. Li WR, Xie XB, Shi QS, Zeng HY, Ou-Yang YS, Chen YB. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl. Microbiol. Biotechnol. 85(4), 1115–1122 (2010).
    1. Miyazawa N, Hakamada M, Mabuchi M. Antimicrobial mechanisms due to hyperpolarisation induced by nanoporous Au. Sci. Rep. 8(1), 3870 (2018).
    1. Elumalai K, Velmurugan S. Green synthesis, characterization and antimicrobial activities of zinc oxide nanoparticles from the leaf extract of Azadirachta indica (L.). Appl. Surf. Sci. 345, 329–336 (2015).
    1. Jamdagni P, Khatri P, Rana J. Green synthesis of zinc oxide nanoparticles using flower extract of Nyctanthes arbor-tristis and their antifungal activity. J. King Saudi Univ. Sci. 30, 168–175 (2018).
    1. Fuerst JA, Sagulenko E. Protein uptake by bacteria. Commun. Integr. Biol. 3, 572–575 (2010).
    1. Zodrow K, Brunet L, Mahendra S. et al. Polysulfone ultrafiltration membranes impregnated with silver nanoparticles show improved biofouling resistance and virus removal. Water Res. 43, 715–723 (2009).
    1. Weiss RC, Cox NR, Martinez ML. Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis. Res. Vet. Sci. 55(2), 162–172 (1993).
    1. Ahmed EM, Solyman SM, Mohamed N, Boseila AA, Hanora A. Antiviral activity of ribavirin nano-particles against measles virus. Cell Mol. Biol. (Noisy-le-grand) 64(9), 24–32 (2018).
    1. Di Stefano G, Colonna FP, Bongini A, Busi C, Mattioli A, Fiume L. Ribavirin conjugated with lactosaminated poly-L-lysine. Biochem. Pharmacol. 54, 357–363 (1997).
    1. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. 1282, 1–23 (2015).
    1. Ding Y, Jiang Z, Saha K. et al. Gold nanoparticles for nucleic acid delivery. Mol. Ther. 22(6), 1075–1083 (2014).
    1. Bolhassani A, Milani A. Small interfering RNAs and their delivery systems: a novel powerful tool for the potential treatment of HIV infections. Curr. Mol. Pharmacol., (2020) (Epub ahead of print).
    1. Suffian IFM, Wang JT, Faruqu FN. et al. Engineering human epidermal growth receptor 2-targeting hepatitis B virus core nanoparticles for siRNA delivery in vitro and in vivo. ACS Appl. Nano Mater. 1(7), 3269–3282 (2018).
    1. Nur SM, Hasan MA, Amin MA, Hossain M, Sharmin T. Design of potential RNAi (miRNA and siRNA) molecules for middle east respiratory syndrome coronavirus (MERS-CoV) gene silencing by computational method. Interdiscip. Sci. Comput. Life Sci. 7, 257–265 (2015).
    1. Sohrab SS, El-Kafrawy SA, Mirza Z, Kamal MA, Azhar EI. Design and delivery of therapeutic siRNAs: application to MERS-coronavirus. Curr. Pharm. Des. 24(1), 62–77 (2018).
    1. Khan MA, Wu VM, Ghosh S, Uskoković V. Gene delivery using calcium phosphate nanoparticles: optimization of the transfection process and the effects of citrate and poly(L-lysine) as additives. J. Coll. Interface Sci. 471, 48–58 (2016).
    1. Cesbron Y, Shaheen U, Free P, Lévy R. TAT and HA2 facilitate cellular uptake of gold nanoparticles but do not lead to cytosolic localisation. PLoS ONE 10, e0121683 (2015).
    1. Docter D, Westmeier D, Markiewicz M, Stolte S, Knauer SK, Stauber RH. The nanoparticle biomolecule corona: lessons learned – challenge accepted? Chem. Soc. Rev. 44, 6094–6121 (2015).
    1. Lundqvist M, Stigler J, Cedervall T. et al. The evolution of the protein corona around nanoparticles: a test study. ACS Nano 5(9), 7503–7509 (2011).
    1. Ezzat K, Pernemalm M, Pålsson S. et al. The viral protein corona directs viral pathogenesis and amyloid aggregation. Nat. Commun. 10(1), 2331 (2019).
    1. Zeltins A. Construction and characterization of virus-like particles: a review. Mol. Biotechnol. 53(1), 92–107 (2013).
    1. Jeevanandam J, Pal K, Danquah MK. Virus-like nanoparticles as a novel delivery tool in gene therapy. Biochimie 157, 38–47 (2019).
    1. Naskalska A, Dabrowska A, Nowak P. et al. Novel coronavirus-like particles targeting cells lining the respiratory tract. PLoS ONE 13(9), e0203489 (2018).

    2. • Study harnessing the coronavirus foes for ‘friendly’ purposes, that is, for creating nanoparticles targeting the alveolar epithelium.

    1. Shen ZT, Sigalov AB. SARS coronavirus fusion peptide-derived sequence suppresses collagen-induced arthritis in DBA/1J Mice. Sci. Rep. 6, 28672 (2016).
    1. Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav. Immun. (2020) (Epub ahead of print).
    1. Petković S. The traces of roman metallurgy in Eastern Serbia. J. Mining Metallurg. B Metallurg. 45(2), 187–196 (2009).
    1. Schumacher F. The ore deposits of Jugoslavia and the development of its mining industry. Econ. Geol. 49, 451–492 (1954).

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi